注射用重组人脑利钠肽不良反应的文献计量学分析

Bibliometric analysis of adverse reactions to recombinant human brain natriuretic peptide for injection

摘要:

目的 分析注射用重组人脑利钠肽药物不良反应（ARD）的发生、分布、严重程度及有效防治措施，为促进临床合理使用注射用重组人脑利钠肽提供可行性用药参考。方法 检索中国知网（CNKI）、中国生物医学文献服务系统(SinoMed)、维普、PubMed、Web of Science数据库关于注射用重组人脑利钠肽ADR的文献，截止到2024年6月30日。使用Excel软件对发文量以及注射用重组人脑利钠肽ARD的病例数量、ADR类型和防治措施进行计量学分析。结果 本文共纳入统计文献125篇，病例6046例，其中明确发生与注射用重组人脑利钠肽使用相关的ADR 628例，总ADR发生率为10.39%（628/6046）。ADR类型包括低血压、低钠血症、头晕头疼等。结论 注射用重组人脑利钠肽在常规剂量下临床使用疗效好，ADR发生率较低，安全性高，但对于可能发生的ADR仍需给予足够的重视。注射用重组人脑利钠肽采用维持量连续给药方式或降低维持给药剂量，疗效与常规剂量相当，还可降低ADR发生率，值得临床医生借鉴。

Abstract:

Objective To analyse the occurrence, distribution, severity and effective prevention and control measures of adverse reactions (ARD) in clinical application of recombinant human brain natriuretic peptide for injection, in order to promote the rational use of recombinant human brain natriuretic peptide for injection in the clinic to provide feasible medication reference.

Methods Literature on ADR to recombinant human brain natriuretic peptide for injection was searched on China Knowledge (CNKI), China Biomedical Literature Service (SinoMed), Weipu, PubMed, Web of Science databases up to 30 June 2024. Excel software were used to perform econometric analyses of the number of publications as well as the number of cases, types of ADR, and preventive and curative measures for ADR of recombinant human brain natriuretic peptide for injection.

Results A total of 125 statistical papers with 6046 cases were included in this paper, of which 628 cases of ADR related to the use of recombinant human brain natriuretic peptide for injection clearly occurred, with an overall ADR incidence of 10.39% (628/6046). The types of ADR included hypotension, hyponatraemia, dizziness and headache, and so on.

Conclusion The clinical efficacy of recombinant human brain natriuretic peptide for injection is good at conventional doses, with a low incidence of ADRs and a high degree of safety, but the possibility of ADR still needs to be given sufficient attention. The efficacy of recombinant human brain natriuretic peptide for injection is comparable to that of conventional dosage, and the incidence of ADR can be reduced if recombinant human brain natriuretic peptide for injection is administered in a continuous maintenance dosage, or at a lower maintenance dosage, which is worthwhile for clinicians to learn from.